The HemOnc Pulse Live at ASH: Jeffrey Lancet, MD, on Targeted Therapies for AML

Watch as Chadi Nabhan, MD, MBA, FACP, interviews Jeffrey Lancet, MD, of the Moffit Cancer Center, at the 64th ASH Annual Meeting. Dr. Lancet and Dr. Nabhan discussed strategies for treating older patients with acute myeloid leukemia (AML), as well as updates presented during the meeting on AML therapies such as menin inhibitors and antibody-drug conjugates.